On August 1, 2026, Divi's Laboratories Limited announced its consolidated unaudited financial results for the quarter ended June 30, 2026, as per the exchange filings.
The company reported a total income of ₹3,144 crore and net profit of ₹902 crore for the quarter ended June 30, 2026.
The company reported a total income of ₹3,144 crore, marking a 24.3% year-on-year (YoY) increase from ₹2,529 crore in the same quarter of the previous year.
The quarter-on-quarter (QoQ) growth was 5.3% from ₹2,986 crore in the March 2026 quarter.
In the June 2026 quarter, Divi's Laboratories saw a significant increase in its net profit (PAT), which rose 65.5% YoY to ₹902 crore from ₹545 crore a year ago.
Compared to the March 2026 quarter, the net profit increased by 20.1% from ₹751 crore. This growth reflects the company's strong performance in the first quarter of the financial year 2026.
For the financial year 2026, Divi's Laboratories reported a total income of ₹11,067 crore. The company's net profit for the fiscal year stood at ₹2,568 crore. These figures indicate a robust financial performance throughout the year.
The company encountered currency fluctuations during the reporting period. Both consolidated and standalone financials reflect a foreign exchange loss of ₹7 crores for the quarter ended June 30, 2026.
This stands in contrast to a foreign exchange gain of ₹39 crores logged during the corresponding quarter of the previous financial year.
The Board of Directors approved key executive appointments during their meeting on August 1, 2026.
Following recommendations from the Nomination and Remuneration Committee, Mr. B. Vara Prasad and Mr. J. Srinivasa Rao were designated as Senior Management Personnel.
Both executive appointments took effect immediately on the board meeting date.
Mr. B. Vara Prasad, the General Manager of Engineering Purchase, has been with the firm since 1994 and brings 31 years of pharmaceutical supply chain experience.
He continues to oversee all engineering-related procurement, managing high-value capital equipment and sustainable energy installations.
Mr. J. Srinivasa Rao, the General Manager of Raw Materials Purchase, joined the company in 1995. Backed by 30 years of industry experience, he coordinates Title:
Divi's Laboratories maintains a single reportable business segment, focusing on manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients. The company operates no discontinued business channels.
The consolidated results encompass the parent listed entity along with two wholly owned international subsidiaries: Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.
Read More: SJVN Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 47.1% YoY!
As of July 31, 2026, at 3:30 PM, Divi's Laboratories share price on NSE was closed at ₹8,056.00, up by 2.82% from the previous closing price.
Divi's Laboratories reported a 24.3% YoY increase in total income to ₹3,144 crore for Q1 2026, with a net profit rise of 65.5% YoY to ₹902 crore. For FY26, total income was ₹11,067 crore, and net profit was ₹2,568 crore.
Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Aug 1, 2026, 4:39 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
